A multicentre, randomized, controlled, phase III clinical study of 230 patients revealed a significant improvement in progression-free survival in patients treated with ivosidenib, a small-molecule targeted inhibitor of mutant IDH1, suggesting that targeting IDH1 mutations in advanced IDH1-mutant CCA could have a significant clinical benefit [116]. This evidence concerns the gene IDH1 and cholangiocarcinoma.